Moderna Stock Soars as Personalized Cancer Vaccine Succeeds in Phase 3 Trial With Merck
Moderna and Merck reported positive Phase 3 trial data for their personalized mRNA cancer vaccine, driving Moderna shares up nearly 150% in morning trading.
Archive
Moderna and Merck reported positive Phase 3 trial data for their personalized mRNA cancer vaccine, driving Moderna shares up nearly 150% in morning trading.
